Literature DB >> 1672604

Pharmacology of celiprolol.

W J Louis1, O H Drummer, L H Tung.   

Abstract

The pharmacology of celiprolol and its relationship to some other beta-adrenoceptor antagonists is described. Celiprolol is a potent beta blocker on beta 1-adrenoceptors and exhibits cardioselectivity both in vitro and in vivo in the pithed rat, but shows no significant in vitro alpha 1-blocking action. Celiprolol differs from atenolol in that it has an intrinsic sympathomimetic activity (ISA) for beta 1-adrenoceptors, which is reflected in its relative lack of negative inotropic effects in humans. In the pithed rat, celiprolol's ISA was demonstrated at much lower doses than for pindolol, even though pindolol has a similar potency to celiprolol in antagonizing the heart rate effects of isoproterenol. It was completely blocked by propranolol, indicating that celiprolol behaves like a partial agonist for beta 1-adrenoceptors, whereas the ISA developed by pindolol was only partially blocked by propranolol. These data suggest a different mechanism for the development of ISA between celiprolol and pindolol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672604     DOI: 10.1007/bf00114234

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  15 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

Review 2.  Effects of antihypertensive drugs on cardiovascular risk factors.

Authors:  L G Howes; W J Louis
Journal:  Clin Exp Pharmacol Physiol       Date:  1988-03       Impact factor: 2.557

3.  Celiprolol--review of airways studies.

Authors:  P Dorow
Journal:  Am J Cardiol       Date:  1988-02-10       Impact factor: 2.778

4.  Actions of dilevalol on adrenoceptors.

Authors:  W J Louis; O H Drummer; L H Tung
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

5.  Celiprolol, clinical dosage, efficacy and safety in asthmatic and elderly patients.

Authors:  G Hitzenberger
Journal:  Br J Clin Pract Suppl       Date:  1985-06

6.  A study of the relationship between cardiac beta-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines.

Authors:  A Bilski; H H Robertson; J L Wale
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 Jan-Feb       Impact factor: 2.557

7.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

Authors:  W P Castelli; R J Garrison; P W Wilson; R D Abbott; S Kalousdian; W B Kannel
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

8.  Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.

Authors:  L H Opie
Journal:  Am J Cardiol       Date:  1988-02-10       Impact factor: 2.778

9.  Celiprolol and the heart.

Authors:  S H Taylor
Journal:  Am J Cardiol       Date:  1988-02-10       Impact factor: 2.778

10.  Calcium antagonists inhibit positive chronotropic responses to alpha 1-adrenoceptor activation in rat isolated atria.

Authors:  L H Tung; M J Rand; W J Louis
Journal:  Eur J Pharmacol       Date:  1987-01-13       Impact factor: 4.432

View more
  6 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  Exercise metabolism in healthy volunteers taking celiprolol, atenolol, and placebo.

Authors:  A Head; S Maxwell; M J Kendall
Journal:  Br J Sports Med       Date:  1997-06       Impact factor: 13.800

Review 3.  Do partial agonist beta-blockers have improved clinical utility?

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 4.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 5.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

6.  Celiprolol: A Unique Selective Adrenoceptor Modulator.

Authors:  James J Nawarskas; Angela Cheng-Lai; William H Frishman
Journal:  Cardiol Rev       Date:  2017 Sep/Oct       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.